Open in interactive viewer → charts, metric popovers & call review

Claritev Pulls 2028 Into 2027 — the Balance Sheet Didn't Get the Memo

A ninth straight quarter of growth, a bookings machine running 70–90% ahead of last year, and an equity 43% off its August high: inside the gap between the story and the stub.
CTEV · Earnings Call · 2026-11-09

The best quarter, the worst tape

Claritev's third quarter was, by its own operating scorecard, the best it has produced in years. Revenue of $268.3 million rose 9.1% year over year — the sixth consecutive quarter of year-over-year growth and the highest quarterly top line in seventeen quarters. Adjusted EBITDA of $162 million was the highest absolute dollar figure in sixteen quarters, and trailing-twelve-month revenue crossed $1 billion for the first time since early 2023. Travis Dalton opened with the line he has been building toward for two years: “we are delivering on the turn and the way up” — Travis Dalton, President and Chief Executive Officer · 2026-11-09. The market has not signed off. The stock sits 43% below its mid-August peak of $42.22 and is down 11% over the last ninety days, against a full-history pattern that reads like a levered equity stub: a 302% run over 24 weeks, then a pair of drawdown legs totalling roughly 78%. When the operating news is this good and the tape this bad, the disagreement is almost never about the quarter. It is about what the quarter is sitting on top of.

I think our Q3 results and the preliminary color we are providing on 2027 can only be described in one way: Claritev is a growth company.

Travis Dalton, President and Chief Executive Officer · 2026-11-09
That is a deliberate rhetorical promotion — from turnaround, to transformation, to growth. The rest of the call is an argument for it.

What actually changed

Three things, and all three are measurable rather than atmospheric. First, bookings. Claritev booked $27 million of ACV in the quarter, taking year-to-date to more than $100 million against $67 million for all of 2025, with full-year guidance raised to $115–125 million. Just as important is the mix: more than half of year-to-date ACV bookings came from outside the core payer vertical, 26% from TPA and 25% from provider, public sector and international, with 78% sourced from the existing client base. Forty-six net new logos over two years is a real, if modest, widening of the funnel. Second, the calendar. Doug Garis pulled the 2028 Investor Day revenue target forward by a full year: “we're running about a year ahead of the financial plan targets we outlined in March” — Doug Garis, Chief Financial Officer · 2026-11-09. At least $1.1 billion of revenue is now expected in 2027 rather than 2028. That is the single most consequential sentence on the call, and it is why the 2027 preliminary guidance landed as a statement of confidence rather than a placeholder. Third — and this is the quiet reversal — claims volume. In August, management was braced for decline: “We basically modeled a low single-digit volume decline on the full year.” — Doug Garis, Chief Financial Officer · 2026-08-07 Nine months in, PSAV claims volumes are up 8% year over year, submitted charges up 15%, and “We're 2 to 3 points ahead of where we planned” — Doug Garis, Chief Financial Officer · 2026-11-09. Dispute initiations in the NSA business are up 75% year over year, and management claims performance 8 points better than the industry average. Savings dollars exceeded $5 billion for the first time in four or five years. The claim volume swing from modelled headwind to realized tailwind is the mechanical reason the full-year guide rose $30.5 million at the midpoint.

The crack, dressed as strength

The most interesting thing management did on this call was reframe a segment miss it had previously called temporary. In August, the Payment & Revenue Integrity shortfall was framed as a calendar problem: “The miss is timing, we still expect that business to be up versus prior year.” — Doug Garis, Chief Financial Officer · 2026-08-07 On Monday the explanation hardened into structure: the legacy clinical negotiation business — roughly a third of the segment — is losing volume as clients migrate to Claims Intelligence solutions. “This is pure geography.” — Doug Garis, Chief Financial Officer · 2026-11-09 Translation: it is cannibalization, mostly internal, and it flatters the largest and most profitable business while hollowing out a smaller one. Ex that piece, PRI was about flat; the segment is now expected to return to growth in 2027, a phrase that appears in the company's keyword set for the first time this quarter (return to growth). There is a defensible case here — over four quarters Claritev booked north of $40 million of PRI ACV, only about 20% of which has converted to revenue, so the forward pipeline is genuinely loaded. But note what has happened to the narrative architecture: the largest business, Claims Intelligence business, is now growing 17.1% and absorbing revenue that used to belong to another segment. Concentration risk has not disappeared; the segments have simply been renamed around it. The rebrand of "Analytics" into Claims Intelligence is the tell — the word Intelligence was the company's fastest-rising term of the quarter.

An AI story that is everyone's AI story

Claritev's innovation narrative — Clara, an AI agent inside Claritev Healthcare Intelligence, transparency-based pricing built on machine-readable-file data, dozens of agents in production, 53% of code AI-generated in Q1 heading to 60–80% by year end — is credible and unusually well-grounded for a company this size, because the data and the workflow already exist. But it is also indistinguishable from the ambient chorus. Across this reporting cycle, Airbnb talked about a chat agent for everything, Lemonade about the emergence of personal AI agents, NICE about the personal-agent era. Claritev's talk of agentic workflows at lightning speed is the same language, and the CEO knows it: “I can sit here and say AI 30 times, like a lot of people do on calls.” — Travis Dalton, President and Chief Executive Officer · 2026-11-09 The honest read is that AI is a margin lever here — fewer people doing more claims work — far more than it is a new revenue line, and management was careful not to quantify it beyond R&D as a percentage of revenue drifting from 16.5% toward 16% and lower.

The part the tape is pricing

Here is the asymmetry. Claritev carries $4.6 billion of effective net cash, negative, leverage of 7.7x (improved a tenth of a turn), $10.1 million of unrestricted cash and $95 million drawn on the revolver. Liabilities now exceed assets: liabilities at 106% of assets. Against that, full-year free cash flow guidance is $10–20 million, and Q3 was a cash consumption quarter by design. The GAAP bridge is still unfinished. Operating income was -$77 million in the last reported quarter while revenue of $257 million sat 15% below its 2022 peak. Capital spending is running near 15 cents on the revenue dollar (capex as a share of revenue), which is the same money that could otherwise be deleveraging. So the operating inflection is real, and the bookings diversification is real, and the pull-forward of the 2027 target is real. But with a $385 million equity stub riding $4.6 billion of debt, every marginal point of EBITDA is worth an outsized amount of market value in both directions — which is precisely why the stock ran 302% in 24 weeks and then gave back two-thirds of it. "Growth company" is a claim the income statement has not yet countersigned. The things to watch are narrow and specific: whether PRI actually returns to growth in 2027, whether the 2-to-4-quarter ACV conversion cadence holds as the mix shifts to longer public-sector installs, and whether free cash flow ever gets large enough to start eating the debt rather than merely servicing it.